About this trial
The first aim of this study is to validate a tool which is used to divide patients into groups based on the molecular sub-type of their tumour.
The other aims of this study are:
To validate some new classifiers (COLOSSUS, ANGIOPREDICT and CMS) as a way of predicting how somone will respond to chemotherapy in patients with MSS RAS mutant colorectal cancer
To compare progression free survival depending on differences in patient’s biomarkers
To assess if it is feasible to generate multiomics results in a potentially actionable time-frame
This study is open to men and women over 18 years of age with metastatic colorectal cancer. Patients must have a type of tumour, called microsatellite stable RAS mutant.
Where’s this trial being run?Bon Secours Cork, Tallaght University Hospital, and University Hospital Galway
Can I join this study / trial?
The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.
Why not Print this page and bring it with you. It will help your doctor and research team advise you.Print this page
For more detailed informationClick Here
Identification of new patient stratification tools in microsatellite stable (MSS) RAS mt metastatic Colorectal Cancer (mCRC).
|Principal Investigator:||Prof Ray McDermott (Tallaght University Hospital)|
Cancer Trials Ireland
Global: September 2018
Ireland: September 2018
|Global Recruitment Target:||163|
|Ireland Recruitment Target:||85|